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Abstract 17 
Staphylococcus aureus is a human commensal but also has devastating potential as an 18 
opportunist pathogen.  S. aureus bacteraemia is often associated with an adverse outcome. To 19 
identify potential targets for novel control approaches we have identified S. aureus components 20 
that are required for growth on human blood. An ordered transposon mutant library was 21 
screened, identifying 9 genes involved specifically in haemolysis or growth on human blood agar 22 
compared to the parental strain. Three genes (purA, purB and pabA) were subsequently found to 23 
be required for pathogenesis in the zebrafish embryo infection model. The pabA growth defect 24 
was specific to the red blood cell component of human blood, showing no growth difference 25 
compared to the parental strain on human serum, human plasma, sheep or horse blood. PabA is 26 
required in the tetrahydrofolate (THF) biosynthesis pathway. The pabA growth defect was found 27 
to be due to a combination of loss of THF-dependent dTMP production by the enzyme ThyA and 28 
an increased demand for pyrimidines in human blood. Our work highlights pabA and the 29 
pyrimidine salvage pathway as potential targets for novel therapeutics and suggests a previously 30 
undefined role for a human blood factor in the activity of sulphonamide antibiotics. 31 
 32 
Introduction 33 
Pathogenicity of the Gram-positive bacterium Staphylococcus aureus requires a 34 
multitude of virulence factors that are intricately co-ordinated and regulated (1, 2). In addition to 35 
the more ‘classic’ virulence factors such as pore-forming toxins and superantigens, fundamental 36 
metabolic processes of bacteria are also recognised as a prerequisite for disease. Indeed, the 37 
majority of antibiotics act by disrupting essential metabolic processes (3). However, pathogens 38 
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including S. aureus, have adapted to resist such insults by switching off, or severely reducing the 39 
activity of, aspects of metabolism in order to persist in the presence of antibiotics (4, 5). 40 
Microbial fitness during pathogenesis requires efficient utilisation of available nutrients. 41 
Although the mammalian host is nutrient rich, many are sequestered as a means of inhibiting 42 
pathogen growth, a concept referred to as ‘nutritional immunity’ (6). Strategies to overcome the 43 
nutrient limited environment in vivo are well described in S. aureus and other bacteria, including 44 
the upregulation of peptide or amino acid transport mechanisms (7) and of proteins which enable 45 
the acquisition of nutrients sequestered by the host (8, 9). De novo biosynthetic pathways are 46 
also required to produce essential products not readily available in the environment. Nucleotide 47 
biosynthetic pathways have been identified as critical for the proliferation of Gram-positive 48 
pathogens on human blood (10) yet detailed studies of the growth requirements of S. aureus are 49 
lacking.  50 
To support studies on S. aureus, the Nebraska Transposon Mutant Library (NTML) was 51 
recently constructed in the CA-MRSA USA300 JE2 strain, deposited in the Network on 52 
Antimicrobial Resistance in S. aureus (NARSA) strain repository and made freely available to 53 
registered users (11). This library was created using the mariner based transposon (bursa 54 
aurealis) employing the same methodology as Bae and colleagues (12). To date, the NTML 55 
library has been used to carry out diverse screens to identify genes involved in S. aureus 56 
antibiotic persistence in vitro (13); altered haemolytic activity on rabbit blood agar (11, 14); 57 
polymicrobial interactions (15) and hyaluronidase activity (16).  58 
A comprehensive approach to identify genes involved in the growth of S. aureus on 59 
human blood was undertaken using the NTML library. Genes were then further characterised to 60 
analyse their potential role in human infection. We show that purine biosynthesis is 61 
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indispensable for growth on human blood and in vivo pathogenicity using a zebrafish embryo 62 
model. In addition, a gene involved in tetrahydrofolate biosynthesis, pabA, was also identified as 63 
being required for virulence in vivo and was unable to grow specifically on human blood. The 64 
relationship between human blood, a folate poor environment and S. aureus pyrimidine salvage 65 
pathways was further elucidated. 66 
 67 
Results 68 
Screening of a S. aureus transposon library for growth defects on human blood. The 69 
NTML was screened to define gene disruptions leading to alterations in growth and/or 70 
haemolysis on agar containing human blood as the only nutrient source (see Materials and 71 
Methods). The library was also screened on bovine serum agar and 5% (v/v) sheep blood with 72 
Columbia agar base as comparators to determine human blood specific traits (data not shown). 73 
The Tn insert for each strain identified in the screen was transduced back into the parent strain 74 
(S. aureus JE2) and transductants were rescreened to establish that the mutant phenotype was 75 
associated with each Tn insertion. Fifteen transductants maintained the altered phenotype, nine 76 
of which (purB, purA, pabA, atl, murQ, araC, mecA, odhB and lipA) were taken forward for 77 
further study (Table 1). The remaining six strains had transposon disruptions in genes expected 78 
to produce an altered phenotype when grown on human blood agar (agrA, agrB, agrC, hla, saeR 79 
& saeS) confirming the ability of the screen to identify specific phenotypes. 80 
Phenotypic characterisation of growth defective mutants in vivo. In order to define 81 
genes for further study, pathogenicity of the nine transduced strains in the JE2 background was 82 
assessed using the zebrafish embryo model of systemic S. aureus infection (17). atl, murQ, araC, 83 
mecA, odhB and lipA did not show altered killing in this model (Fig. S1a,b). However, three of 84 
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the strains, harbouring Tn inserts in the purA, purB and pabA genes (herein named JE2-purA, 85 
JE2-purB and JE2-pabA), showed significant attenuation in the zebrafish model (P<0.0001; Fig. 86 
1a). To confirm that the reduced pathogenicity was not strain specific, Tn inserts containing the 87 
purA, purB and pabA genes were transduced into another strain background, S. aureus SH1000. 88 
These strains (herein named SH-purA, SH-purB and SH-pabA) also showed significant 89 
attenuation in the zebrafish embryo model (P<0.0001; Fig. 1b). In vivo growth analysis 90 
demonstrated that SH-purA and SH-purB were unable to replicate within zebrafish embryos and 91 
bacterial numbers recovered were lower than the inoculated dose (Fig. 1c,d). This is in stark 92 
contrast to the bacterial kinetics observed when parental S. aureus is injected at the same dose as 93 
previously published (Fig. S1c) (17). SH-pabA retained limited capacity to replicate and to cause 94 
host death in the zebrafish model (Fig. 1e). Using a knock-down approach to deplete zebrafish 95 
myeloid cells (pu.1 morpholino), SH-pabA was restored to similar virulence as the parental strain 96 
but with a slight temporal delay (Fig. 1f). By 20 hours post infection (hpi), all embryos injected 97 
with the parent strain, and 80% of SH-pabA injected embryos, had succumbed. The remaining 98 
SH-pabA injected embryos died over the following 24 hours. In myeloid depleted zebrafish, SH-99 
purA and SH-purB caused death of approximately two thirds of subjects injected, significantly 100 
less than the parent strain (P<0.0001). The pu.1 knockdown approach causes a temporary delay 101 
in phagocytic cell development and as expected, no further host death was observed after 40 102 
hours, a time point at which recovery of phagocyte production would occur (18, 19). 103 
Purine biosynthesis is required for growth in blood. Analysis of the purA and purB 104 
genes (20, 21) demonstrated that purA and purB code for enzymes in the purine biosynthesis 105 
pathways (adenylosuccinate synthase and adenylosuccinate lyase respectively) (Fig. S2). In 106 
vitro, JE2-purA and JE2-purB showed reduced growth on human blood and bovine serum agar 107 
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plates, but growth similar to the parent strain on 5% (v/v) sheep blood which contains a rich 108 
nutrient base (data not shown). Growth assays of JE2-purA and JE2-purB in liquid media were 109 
also conducted (BHI, bovine serum or human serum) (Fig. 2a-c). Growth was comparable to the 110 
parent only in nutrient rich BHI media, matching that seen in the initial NTML screen. This 111 
suggested that the reduced growth phenotype was due to a nutrient requirement not readily 112 
available in human blood or human/bovine serum. Analysis of the purine biosynthesis pathway 113 
suggested that both strains should require adenine for growth, whilst in addition to adenine, JE2-114 
purB should also require guanine (or inosine). Chemically defined media (CDM) analysis 115 
confirmed that purA growth was dependent on the presence of adenine and purB growth was 116 
dependent on adenine and guanine (Table 2; Fig. 2d). Addition of 20 μg ml-1 adenine and 20 μg 117 
ml
-1
 inosine restored growth of each pur mutant, to similar levels obtained for the parent strain 118 
(data not shown). Biochemical complementation of purA and purB was not successful in the 119 
zebrafish infection model, likely due to poor diffusion of nucleobases into zebrafish embryos 120 
(data not shown). The importance of purine biosynthesis pathway enzymes in disease has been 121 
well characterised (22, 23).  122 
pabA is required for virulence in the murine sepsis model and growth in human 123 
blood. In a mouse sepsis model, mice injected with S. aureus SH-pabA (4 x 10
7
 CFU) lost 124 
significantly less weight compared to those receiving the parent strain (2 x 10
7
 CFU). Bacterial 125 
numbers were also significantly lower in kidneys harvested from mice injected with SH-pabA 126 
(Fig. 3a,b; P<0.01).  127 
The pabA Tn mutant was found to have a unique growth phenotype in the initial screen. 128 
Growth was highly reduced on 30% (v/v) human blood but had only slightly reduced growth on 129 
30% (v/v) rabbit blood (Table 1). However, pabA grew well on both sheep and horse blood agar 130 
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(30% v/v) demonstrating that the phenotype was species specific. In addition, pabA 131 
demonstrated good growth on 50% (v/v) human serum or plasma agar (Fig. S3). To ascertain if 132 
the amount of human plasma in 30% (v/v) whole blood agar was too low to support growth, 133 
pabA was compared to the parent strain on agar increasing in plasma concentration up to 50% 134 
(v/v). At the lower concentrations of 10% (v/v) and 15% (v/v) (15% being the approximate 135 
plasma concentration in 30% (v/v) blood agar) growth of pabA was poor, but comparable to JE2 136 
which also displayed poor growth at this concentration. Therefore, the reduced pabA growth on 137 
human blood was not a result of lower plasma levels in human blood agar (data not shown).  138 
PabA is an enzyme required for tetrahydrofolate (THF) synthesis (para-aminobenzoate 139 
synthetase component II) (20) and pabA is found in an operon with pabB and pabC, which is 140 
responsible for the synthesis of the folate pathway intermediate, 4-aminobenzoic acid (PABA) 141 
(20). Strains from the NTML harbouring a Tn disrupting pabB or pabC were transduced into the 142 
SH1000 background and also found to be attenuated in the zebrafish infection model (Fig. 3c,d; 143 
P<0.001). Genetic complementation of the pab operon restored JE2-pabA growth on human 144 
blood (Fig. 3e) and SH-pabA virulence in the zebrafish model (Fig. 3f). 145 
Reduced growth on human blood could be due to lack of nutrients that are required by a 146 
THF-lacking strain. The end-product of the folate pathway, THF, acts as single-carbon 147 
donor/acceptor in glycine/serine interconversion, vitamin B5 synthesis, methionine synthesis, 148 
purine synthesis, N-formylmethionine-tRNA charging, glycine cleavage and deoxythymidine 149 
monophosphate (dTMP) synthesis (Fig. S4). To further characterise pabA, different media were 150 
used to interrogate the mechanism underpinning the lack of growth on human blood. In liquid 151 
culture, pabA growth was comparable to that of the wildtype in both BHI, bovine and human 152 
serum (data not shown) suggesting that the reduced growth phenotype was specific to blood. 153 
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Using CDM base media lacking purines, serine and glycine, only the addition of purines, serine 154 
and glycine together could restore growth yield of the mutant to parental levels (as measured by 155 
maximum OD600 reached) (data not shown). Biochemical complementation with the same 156 
supplements did not restore growth of pabA on human blood, nor did addition of folic acid. 157 
However, addition of PABA fully complemented growth (Fig. S5a) as would be expected based 158 
on similar work done in Lactococcus lactis (24). Immersion of zebrafish embryos injected with 159 
SH-pabA into E3 medium containing PABA, restored virulence in vivo (Fig. 3g; P<0.0001). 160 
Pyrimidine salvage pathways are required to bypass pabA. Synthesis of dTMP is 161 
achieved via a THF-dependent route, or via an alternative nucleotide salvage pathway requiring 162 
thymine or thymidine (Fig. 4a). A combination of glycine, serine and purines could not restore 163 
growth of pabA on human blood, however, the addition of pyrimidines (thymine) supported 164 
growth to the extent of the parent strain, JE2 (Fig. S5a). The crucial role of pyrimidines in 165 
bacterial survival under folate deprived conditions has been reported previously (25, 26). Neither 166 
pyrimidines, nor folic acid, could restore pathogenicity of pabA in the zebrafish embryo model 167 
(data not shown). 168 
Double mutants defective in pabA and one of the pyrimidine nucleotide salvage pathway 169 
genes pdp, tdk or the thymidine transporter gene, nupC, were constructed to assess their role in 170 
pabA growth. Growth of all three double mutants was reduced on human blood but could be 171 
complemented with PABA (Fig. S5b). Thymine and thymidine addition to blood could 172 
complement all mutants except for the pabA tdk double mutant. This highlighted that pyrimidine 173 
salvage pathways are required to bypass the deficit of pabA and if an inhibitory factor in blood 174 
was responsible for preventing pabA growth, Tdk is the likely target. Unexpectedly, the pabA 175 
pdp double mutant was complemented by thymine and the pabA nupC mutant was 176 
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complemented by thymidine. This suggests that conversion of thymine to thymidine can be 177 
achieved independently of Pdp and that an alternative thymidine transporter to NupC is available 178 
in S. aureus. Two remaining putative pyrimidine transporters have been identified in S. aureus 179 
and not yet investigated (27).  180 
Investigating a nucleotide salvage pathway inhibitory component in human blood. 181 
The nucleotide salvage pathway appears to provide enough dTMP (later converted to dTTP) for 182 
DNA synthesis and growth of pabA on human plasma/serum, but not on human blood, unless 183 
thymine/thymidine is added. This suggested that a factor in whole blood either competitively 184 
inhibits the nucleotide salvage pathway enzymes, or that growth on human blood leads to an 185 
increased requirement for dTMP, which cannot be met without increasing the thymine/thymidine 186 
concentration (Fig. 4a). To hone in on an inhibitory factor, different components of blood were 187 
assessed for their ability to replicate the pabA poor growth phenotype seen on whole human 188 
blood. JE2-pabA growth was comparable to JE2 on platelet rich plasma (PRP) and on PRP that 189 
had been vortexed to disrupt platelets (data not shown). Similarly, parent and mutant growth 190 
were equivalent when white blood cells (WBCs), either intact or lysed, were added to platelet 191 
poor plasma (PPP). Vortexing of whole human blood followed by centrifugation produces red, 192 
rather than straw coloured, plasma, indicating RBC lysis. Plasma from vortexed blood was 193 
mixed with PPP to give a 9:1 ratio of non-vortexed to vortexed plasma, decreasing incrementally 194 
to a ratio of 1:9. At the lowest ratio of non-vortexed to vortexed plasma the growth of JE2-pabA 195 
was highly reduced (Fig. 4b). This suggested that there is a potent inhibitor of pabA growth in 196 
the red blood cell (RBC) component of human blood.  197 
Haemoglobin/haem was deemed a likely candidate for the inhibitory factor. 198 
Haemoglobin, a complex of four heme groups, is the most abundant hemoprotein in humans. 199 
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Heme is an iron containing ring structure and usage of heme as an iron source can be toxic to 200 
bacteria due to its active redox potential (28). Though the mechanisms underlying this are not 201 
fully understood, it has been reported that heme induced monooxygenase like activity can cause 202 
direct DNA damage (28, 29). In S. aureus, haem is extracted from haemoglobin and transported 203 
into the cell by the iron regulated surface determinant system (Isd system) (30). Toxicity induced 204 
by liberation of iron from heme by S. aureus is reduced by the two component heme-regulated 205 
transporter (hrtAB). Haem is also transported into S. aureus by the ABC transporter HtsABC, 206 
which requires haem extraction from haemoglobin by the Isd system (30). Both transport 207 
systems are upregulated in low Fe by alleviation of the negative regulator Fur. However, 208 
supplementing human blood agar with an alternative Fe source (ammonium ferrous sulphate) did 209 
not support growth of JE2-pabA on human blood (data not shown). In addition, lyophilised 210 
bovine haemin, bovine haemoglobin and human haemoglobin did not prevent pabA growth on 211 
plasma (data not shown).  212 
S. aureus growth in human blood requires an increased demand for pyrimidines. 213 
Rather than an inhibitory factor in blood preventing pabA growth, it is possible that human blood 214 
leads to an increased requirement for dTMP, which cannot be met in a folate-deficient mutant 215 
reliant solely on the pyrimidine salvage pathway (Fig. 4a). Thymidylate synthase (thyA) is highly 216 
conserved, requiring THF as a cofactor for conversion of dUMP to dTMP, an essential step in 217 
DNA synthesis. To maintain viability, thyA mutants can utilise extracellular thymidine, via 218 
pyrimidine salvage pathways (31) and thus cannot grow in-vitro on media lacking pyrimidines 219 
such as Mueller-Hinton (MH) agar or human blood (27). To determine if human blood increases 220 
the demand for pyrimidines, a minimal permissive concentration of thymidine to allow thyA 221 
growth (500 ng ml
-1
) was added to MH agar (Fig. 5a). As the added concentration of human 222 
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blood increased, ranging from 1-50% (v/v), thyA growth became increasingly inhibited, 223 
suggesting that as for pabA, pyrimidine requirements are elevated by human blood. This was 224 
further confirmed by addition of higher concentration thymidine (400 μg ml-1) which allowed 225 
biochemical complementation of thyA (Fig. 5b). 226 
In the host environment, when innate immune cells encounter bacteria, reactive oxygen 227 
species (ROS) such as superoxide and nitric oxide are generated (32). Bacteria have developed 228 
sophisticated mechanisms to resist such oxidative stress. Although heme acquisition is a 229 
necessity for S. aureus survival in vivo, we hypothesised that heme causes bacterial oxidative 230 
stress requiring increased dTTP requirements for DNA repair and pabA would be less able to 231 
compensate, compared to the parent strain. To test this, the pabA mutation was transduced into a 232 
strain unable to acquire heme due to a disrupted Isd and haem transport systems, LS1ΔisdEΔhtsA 233 
(33). The triple mutant (LS1ΔisdEΔhtsApabA) was inoculated onto human blood agar to 234 
determine if the removal of potential heme toxicity would restore pabA growth. No growth was 235 
observed for pabA or ΔisdEΔhtsApabA on unsupplemented blood agar but both strains displayed 236 
good growth in the presence of exogenous pyrimidines (data not shown). However, it has been 237 
demonstrated that in the absence of functional haem transport and Isd systems, S. aureus can still 238 
acquire haem, by a 3
rd
, as yet unknown, haem transport mechanism (33).  239 
In the presence of sulphonamide antibiotics, nucleotide salvage pathways are 240 
required for S. aureus growth in blood. The effect of folate antagonistic, sulphonamide 241 
antibiotics, such as trimethoprim (TMP), on S. aureus, leads to loss of THF synthesis and similar 242 
to pabA, a dependence on the pyrimidine nucleotide salvage pathway for dTMP synthesis. The 243 
activity of this class of antibiotics can be reversed by providing enough thymine to bypass the 244 
requirement for the THF-dependent dTMP synthesis pathway (34). Pyrimidine reversal of TMP 245 
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activity for JE2, JE2-pabA and JE2-tdk was assessed for growth on human, sheep or horse blood 246 
agar. On human blood, thymidine reversed TMP activity against JE2, and JE2-pabA growth was 247 
restored in the presence of thymidine; however, TMP was active against JE2-tdk in the presence 248 
or absence of thymidine (Table 3). Similar results on horse blood to those seen on human blood 249 
were found. On sheep blood TMP antibiotics were inactive against JE2 and JE2-pabA, likely due 250 
to a higher pyrimidine concentration in sheep blood (35) demonstrating that the JE2-pabA 251 
phenotype on human blood may also be due to differences in blood pyrimidine content. As with 252 
human and horse blood, JE2-tdk was inhibited by TMP on sheep blood and addition of thymidine 253 
could not reverse this, as the nucleotide salvage pathways are prohibited. 254 
 255 
Discussion 256 
In order to identify novel pathogenicity determinants, an ordered library of transposon 257 
mutants was screened for gene disruptions causing growth and haemolysis defects on agar 258 
containing human blood as the only nutrient source. This identified purA, purB and pabA as 259 
being required for growth on human blood. The purA and purB genes are part of the de novo 260 
biosynthetic pathway for purines and pabA is involved in folate synthesis. Confirming an 261 
important role in pathogenesis, all three mutations were found to lead to significant attenuation 262 
in the zebrafish systemic model of infection.  263 
In a study detailing the non-essential genes involved in growth of Escherichia coli, 264 
Salmonella enterica and Bacillus anthracis in human serum using a microarray-based system, 265 
the majority of mutants identified were involved in purine or pyrimidine biosynthesis (10). This 266 
suggests a scarcity of nucleotides in vivo, which bacteria counteract by being equipped with 267 
energy costly metabolic pathways permitting de novo synthesis. Similarly, in our study, the 268 
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ability of purine biosynthesis mutants to grow in nutrient rich media suggested that purA and 269 
purB have a requirement for nutrients not readily available in human serum, whole blood and the 270 
live zebrafish.  271 
The reduced growth of S. aureus pabA in vitro was intriguing as it was specific to human 272 
blood, with normal growth seen on blood components (serum, plasma), horse and sheep blood. 273 
PabA is required for production of PABA, an essential intermediate in the synthesis of THF. A 274 
pabB mutant of Streptococcus pneumoniae has been used as an attenuated strain for vaccine 275 
research highlighting the importance of this pathway in the development of prophylactic 276 
strategies (36). Using CDM liquid and solid agar, purines, glycine and serine were required for 277 
growth by the pabA mutant in excess of that required by the parental strain. However, when 278 
assessed on human blood agar, growth inhibition could not be rescued with any compound 279 
except pyrimidines suggesting that all other necessary factors to bypass the lack of THF, are 280 
present in serum, plasma and whole blood. The concept of ‘thymine-less’ death has been 281 
previously noted and demonstrates the fundamental importance of pyrimidines in bacterial 282 
survival, over and above the other downstream effectors of THF (25). The addition of thymidine 283 
to human blood permitted pabA growth (Fig. S5a). Human blood is known to have a low 284 
thymidine content compared to other animals (35). However, growth of the mutant on other 285 
thymidine poor media (e.g. CDM, horse blood) suggested that thymidine deficiency per se was 286 
not solely responsible for the growth phenotype.  287 
In the absence of THF dependent thyA activity, pyrimidine salvage pathways are essential 288 
to convert thymidine to dTMP (via Tdk) which is necessary for DNA replication. Both pabA and 289 
thyA rely on these salvage pathways to provide a permissive amount of thymidine and therefore, 290 
dTTP, to remain viable. It is difficult to tease apart exactly how human blood subverts this 291 
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process and we hypothesised that Tdk was the target of competitive inhibition in the pabA 292 
mutant, given that supplemental thymidine restored pabA growth and a genetic knockout of pabA 293 
tdk eliminated this biochemical complementation. Double knockouts of pabA with the gene 294 
responsible for conversion of thymine to thymidine (pabA pdp) or a pyrimidine transporter 295 
(pabA nupC) had no effect on biochemical complementation. Furthermore, pabA growth was 296 
reduced on human plasma supplemented with lysed RBC products. As excess haem is toxic to S. 297 
aureus (28), haem and related molecules were ruled out as Tdk inhibitory factors. Tdk is an 298 
enzyme requiring zinc which is purported to be required for transcriptional regulation (37) and 299 
zinc sequestration by human blood and other potential inhibitory factors should be further 300 
investigated in future work (38). 301 
Although the exact mechanism is yet to be elucidated, it is clear however that human 302 
blood, or a component therein, leads to an increased demand for dTMP, which cannot be met in a 303 
THF-deficient mutant, hence why exogenous thymidine/thymine is necessary to support growth 304 
of the mutant specifically on human blood.  305 
Finally, little is known about the clinical prevalence or relevance of pabA mutations. 306 
Trimethoprim is used in the control of S. aureus infections and long-standing treatment can lead 307 
to failure due to development of antibiotic resistance (39). In this context, thyA mutations are 308 
usually observed in the resistant subpopulation and such mutations cause formation of thymidine 309 
dependent small colony variants (SCVs) which rely on pyrimidine salvage pathways (via Pdp 310 
and Tdk) (40). However, these antibiotics remain bacteriocidal, unless a thymidine rich 311 
environment exists, such as damaged host tissues, which allow S. aureus to utilise pyrimidine 312 
salvage pathways and thus survive (41). The work presented here suggests that the activity of 313 
sulphonamide drugs is the result of inhibition of THF coupled with reduced activity of the 314 
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pyrimidine salvage pathways and/or an increased demand for dTMP imparted by human blood. 315 
The identification of metabolic pathways important for host:pathogen interactions provides novel 316 
avenues to be explored to combat antibiotic resistant pathogens. 317 
 318 
 319 
 320 
  321 
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Materials and methods 322 
Ethics statement. Zebrafish embryos less than 5 days post fertilization (dpf) are not 323 
protected under the Animals (Scientific Procedures) Act 1986 but all zebrafish work was carried 324 
out according to the details set out in Project License PPL 40/3574. Murine work was carried out 325 
according to UK law in the Animals (Scientific Procedures) Act 1986, under Project License 326 
PPL 40/3699. Human blood was obtained from healthy volunteers in compliance with the 327 
guidelines of the South Sheffield Research Ethics Committee (STH13927). 328 
Bacterial strains, plasmids and growth conditions. The Nebraska transposon 329 
mutagenesis library (11) was acquired from the Network on Antimicrobial Resistance in S. 330 
aureus (NARSA) strain repository, now available from BEI Resources (www.beiresources.org/) 331 
and used for screening experiments. Originally in the USA300 LAC JE2 background, mutations 332 
were transduced back into JE2 or SH1000 as required. All other strains and the list of plasmids 333 
used in this study are given in Table 4. S. aureus strains were routinely grown in Brain Heart 334 
Infusion (BHI) media at 37
o
C with aeration at 250 rpm, unless otherwise stated. Mueller- Hinton 335 
agar (Oxoid) was as a thymidine poor media where stated. E. coli strains were grown in Luria 336 
Bertani at 37C with aeration at 250 rpm. Agar at 1.5% (w/v) was added for solid media. 337 
Antibiotics were added as required. For MIC determination, a bacterial colony was inoculated 338 
into 2 ml sterile dH2O and spread onto an agar plate using a sterile swab (Oxoid). Trimethoprim 339 
E-tests

 (bioMérieu) were applied to the solid media surface using tweezers and incubated 340 
overnight at 37°C.  341 
The chemically defined media used in this study has been previously described (42). The 342 
following components were dissolved into 1 litre of H2O: Na2HPO4.2H2O, 7g; KH2PO4, 3g; L-343 
Aspartic Acid, 0.15g; L-Alanine, 0.1g; L-Arginine, 0.1g; L-Cysteine, 0.05g; Glycine, 0.1g; L-344 
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Glutamic Acid, 0.15g; L-Histidine, 0.1g; L-Isoleucine, 0.15g; L-Lysine, 0.1g; L-Leucine, 0.15g; 345 
L-Methionine, 0.1g; L-Phenylalanine, 0.1g L-Proline, 0.15g; L-Serine, 0.1g; L-Threonine, 0.15g; 346 
L-Tryptophan, 0.1g; L-Tyrosine, 0.1g; L-Valine, 0.15g; Biotin, 0.02g; Pyridoxal HCl, 0.8g; 347 
Nicotinic Acid, 0.4g; Pyridoxamine di-HCl, 0.8g; D-Pantothenic Acid, 0.4g; Riboflavin, 0.4g; 348 
Thiamine HCl, 0.4g; Adenine Sulphate, 0.02g; Guanine HCl, 0.02g; CaCl2.6H2O, 0.01g; (NH4)-349 
2Fe(SO4)2.6H2O, 0.006g; Glucose, 10g MgSO4.7H2O, 0.5g. Inosine was used as described. 350 
Human, or other animal, blood or blood components were added to agar at varying 351 
concentrations, as required. Venous blood was collected from healthy volunteers following 352 
informed consent. For plasma preparation, blood was centrifuged at 270 g for 20 min in 50 ml 353 
Falcon tubes. The upper platelet rich phase was collected and used directly as platelet rich 354 
plasma (PRP), or centrifuged again at 1155 g for 30 min to give platelet poor plasma (PPP). 355 
Plasma was stored at -20
o
C. Animal blood and blood products were purchased from 356 
Thermoscientific or Sigma and stored at 4
o
C. Bovine haemin/haemoglobin, human haemoglobin, 357 
thymine, thymidine, glycine, serine, vitamin B5, methionine, PABA, folic acid or methyl 358 
viologen (Sigma) was added to media as and when required at the stated concentrations. 359 
Genetic manipulation. Electroporation was used to transform S. aureus RN4220 and E. 360 
coli using previously published methods (43, 44). All S. aureus transduction experiments were 361 
carried out with φ11 as described previously (45).   362 
For genetic complementation of SH-pabA and JE2-pabA, Phusion polymerase (NEB) was 363 
used to amplify the pab operon from S. aureus SH1000 genomic DNA, using primers containing 364 
appropriate restriction sites (forward, ATAATAGGGCCCATTGTA-365 
CTGTCTTGACCACCACT; reverse, ATAATACTCGAGATACGTATACAAGAATTAA-366 
CAACAGCA). The PCR product was inserted into pKASBAR (46), a plasmid encoding an attP 367 
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site. Using this attP site, bacteriophage DNA can integrate into the S. aureus genome at the attB 368 
site, in the presence of an integrase (47). The attB site is located at the glycerol ester hydrolase 369 
(geh) gene so integration can be verified by loss of lipase activity. For such genetic 370 
manipulation, the integrase is provided by an additional helper plasmid, pYL112Δ19, propagated 371 
in the S. aureus recipient strain, RN4220. The insert was then transduced from RN4220 into 372 
pabA and control strains.  373 
To prepare double mutants within Tn insertions, the “toolkit” for switching antibiotic 374 
resistance within NTML strains was used as published previously (48). Tn inserts in pdp, nupC 375 
and tdk genes, with alternate antibiotic resistance markers, were transduced into pabA as listed in 376 
Table 4. 377 
Strains LS1 and LS1ΔisdEΔhtsA were kindly provided by Dr Sean Nair (University 378 
College London). pabA was transduced into both strains and successful transductants were 379 
confirmed by PCR. 380 
Transposon library screen. The NTML was grown for 18 h at 37
o
C in 96-well 381 
microtiter dishes. Using a 96-pin replicator (Boekel Industries), the contents of each well were 382 
transferred to BHI agar, BHI + erythromycin (10 µg/ml)/lincomycin (25 µg/ml) agar, 30% (v/v) 383 
human blood agar, 50% (v/v) bovine serum agar and 5% (v/v) sheep blood, plus Columbia agar 384 
base in rectangular OmniTray plates (Nunc). Human blood and bovine serum plates were 385 
incubated for 48 h at 37
o
C, all other plates were incubated for 18 h at 37
o
C, with an additional 4 386 
h at 4
o
C for sheep blood plates, to ensure efficient haemolysis. Phenotypes were determined by 387 
comparison of each spot (colony size and haemolysis zone) to the surrounding spots on the plate. 388 
Zebrafish model. Zebrafish embryos, strain London wild-type (LWT), were maintained 389 
in E3 medium at 28
o
C, following standard protocols (17). Embryos were bred in the aquarium 390 
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facilities at the University of Sheffield. Microinjection of embryos was performed as described 391 
previously (17). Individual infected embryos were kept in 100 µl E3 media and survival was 392 
assessed over 90 h. For in vivo complementation experiments, compounds were dissolved in E3 393 
medium and buffered to a pH of 6.5-7.5. Immediately following injections, embryos were placed 394 
in compound solutions at the stated concentrations. Further compound solution was added in the 395 
embryo washing step. 96-well microtitre plates were placed in a plastic box, with damp paper, to 396 
reduce evaporation during incubation.  397 
  pu.1-antisense morpholino-modified oligos (49) were injected into zebrafish embryos 398 
using the method described previously (17). Bacteria were recovered from infected embryos at 399 
12 h time intervals. Individual embryos were transferred to microcentrifuge tubes and 400 
homogenised using a PreCellys 24-dual (Peqlab). Bacterial numbers were then determined by 401 
serial dilution in phosphate buffered saline (PBS) and plating onto BHI agar. 402 
Murine infection model. Female BALB/c mice were purchased from Charles River 403 
Laboratories (Margate, UK) and maintained by standard husbandry techniques at the University 404 
of Sheffield (Biological Services). Bacteria were washed in endotoxin free PBS (Sigma) and 100 405 
µl (2-4 x 10
7
 CFU) was injected i.v. into the tail vein. Serial dilutions of culture were prepared to 406 
confirm injection CFU. Mice were monitored and sacrificed at 72 hpi. Mouse organs were 407 
individually homogenised in PBS and after serial dilution, plated onto BHI agar supplemented 408 
with antibiotics as needed for bacterial number enumeration.  409 
Statistical analysis. Sample sizes were predetermined for mouse (n=10) and zebrafish 410 
experiments (n=20) based on previous experimental data (50). All zebrafish experiments are 411 
representative of n=2 unless otherwise stated. For zebrafish embryo survival experiments, the 412 
Kaplan-Meier method was employed. Comparison between survival curves was made using the 413 
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log-rank (Mantel Cox) test. For bacterial count comparison in murine experiments, the Mann-414 
Whitney U test was used. Statistical analysis was performed using Prism version 6.0 (GraphPad) 415 
and P < 0.05 was considered significant.  416 
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Category Protein ID NARSA ID Protein Name 
Growth Phenotype Haemolysis Phenotype 
Human Blood Rabbit Blood 
5% Human Blood + 
Columbia Agar 
5% Sheep Blood + 
Columbia Agar 
A1 
SAUSA300_1889 NE522 adenylosuccinate lyase, PurB Reduced Growth Reduced Growth Increased Haemolysis Reduced Haemolysis 
SAUSA300_0017 NE529 
adenylosuccinate synthetase, 
PurA 
Reduced Growth Reduced Growth Increased Haemolysis 
Slightly Increased 
Haemolysis 
SAUSA300_0698 NE821 
para-aminobenzoate synthase, 
glutamine amidotransferase, 
component II, PabA 
Highly Reduced 
Growth 
Slightly Reduced Growth ------ ------ 
A2 
SAUSA300_0955 NE460 autolysin, Atl Opaque Colony Opaque Colony Increased Haemolysis ------ 
SAUSA300_0193 NE1253 
N-acetylmuramic acid-6-
phosphate etheraur, MurQ 
------ ------ Increased Haemolysis Increased Haemolysis 
SAUSA300_2326 NE1304 
transcription regulatory protein, 
AraC 
------ ------ Reduced Haemolysis ------ 
SAUSA300_0899 NE1315 adaptor protein, MecA ------ ------ Reduced Haemolysis 
Slightly Reduced 
Haemolysis 
SAUSA300_1305 NE1391 
dihydrolipoamide 
succinyltransferase, OdhB 
Slightly Reduced 
Growth 
Slightly Reduced Growth Increased Haemolysis Increased Haemolysis 
SAUSA300_0320 NE1775 triacylglycerol lipase, LipA 
Slightly Reduced 
Growth 
------ Increased Haemolysis ------ 
B 
SAUSA300_1989 NE95 
accessory gene regulator protein 
B, AgrB 
------ ------ ------ Reduced Haemolysis 
SAUSA300_1991 NE873 
accessory gene regulator protein 
C, AgrC 
------ ------ Slightly Reduced No Haemolysis 
SAUSA300_0690 NE1296 sensor histidine kinase, SaeS ------ ------ ------ No Haemolysis 
SAUSA300_1058 NE1354 alpha-hemolysin, Hla ------ ------ ------ No Haemolysis 
SAUSA300_1992 NE1532 
accessory gene regulator protein 
A, AgrA 
------ ------ Reduced Haemolysis No Haemolysis 
SAUSA300_0691 NE1622 
DNA-binding response regulator, 
SaeR 
------ ------ ------ No Haemolysis 
 570 
Table 1 Tn library mutants identified as having altered phenotype on human blood agar 571 
A1 - Strains with a defect in growth on human blood agar which were investigated further; A2 - strains with altered haemolysis on 572 
human blood agar which were investigated further; B - strains expected to show a haemolysis phenotype and not explored further. ---, 573 
No difference from the JE2 control.574 
 o
n
 August 25, 2017 by UNIVERSITY O
F SHEFFIELD
http://iai.asm
.org/
D
ow
nloaded from
 
30 
 
 575 
Strain Name 
Chemically Defined Media 
+Adenine 
+Guanine 
-Adenine 
-Guanine 
+Adenine 
-Guanine 
-Adenine 
+Guanine 
JE2 + + + + 
purB + - - - 
purA + - + - 
 576 
Table 2 Growth analysis on solid media of JE2-purA and JE2-purB in the presence or 577 
absence of adenine and guanine  578 
Adenine 20 μg ml-1; guanine 20 μg ml-1; + growth; - no growth  579 
 580 
 581 
  582 
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 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
Table 3 Minimum inhibitory concentration (MIC, mg/L) of trimethoprim (TMP) of parent, 591 
JE2-pabA or JE2-tdk S. aureus strains on various media 592 
 593 
–T no exogenous thymidine added, +T thymidine (400 g ml-1) added 594 
  595 
 
TMP 
MIC (mg/L) 
BHI Human blood Sheep blood Horse blood 
- T + T - T + T - T + T - T + T 
parent 1 >32 0.75 >32 >32 >32 1 >32 
pabA 1 >32 - >32 >32 >32 >0.002 >32 
tdk 0.25 0.25 0.75 0.75 0.5 0.5 1 1 
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Strain  Relevant genotype/markers  Source/reference 
S. aureus strains 
SH1000 Functional rsbU+ derivative of 8325-4 (51) 
RN4220 Restriction negative, modification positive strain (52) 
USA300 JE2 USA300 LAC strain cured of plasmids p01 and p03 (11) 
SJF4669 SH-pabA::spc, pdp::ery 
 
This study 
SJF4670 SH-pabA::spc, nupC::ery This study 
SJF 4671  
 
SH-thyA::ery 
 
(27) 
SJF4678 pabA::spc, tdk::ery 
 
This study 
JC006 JE2-pabA, pJC002 inserted at lipase – pabA+ EryR LinR TetR This study 
JC007 JE2-pabA, pKASBAR inserted at lipase EryR LinR TetR This study 
JC010 SH-pabA, pJC002 inserted at lipase – pabA+ EryR LinR TetR This study 
JC011 SH-pabA, pKASBAR inserted at lipase EryR LinR TetR This study 
LS1 Spontaneous murine arthritis isolate (53) 
LS1ΔisdEΔhtsA LS1 derivative, ΔisdE ΔhtsA (33) 
E. coli strains 
TOP10  F- mcr Δ (mrr-hsdRMS-mcrBC) Φ 80 lacZ ΔM15 ΔlacX74 recA1 
deoR araD139 Δ(ara-leu) 7697 galK rpsL (StrR) endA1 nupG  
Invitrogen  
Plasmids 
pKASBAR  Hybrid vector of pCL84 and pUC18 for integration into S. aureus 
lipase gene (geh), attP; TetR (S. aureus), SpecR (E. coli)  
(46) 
pJC002 pKASBAR containing the pab operon, pabA, pabB and pabC and 
upstream control elements; TetR 
This study 
Table 4 Strains and plasmids used in this study 596 
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Figure Legends 598 
 599 
Figure 1 In vivo characterisation of S. aureus strains in the zebrafish embryo model of 600 
infection with reduced growth on human blood in vitro 601 
a, Survival curves of fish injected with S. aureus JE2 (1500 CFU, JE2), S. aureus JE2 purA, 602 
purB or pabA (1500 CFU). b, Survival curves of fish injected with S. aureus SH1000 (1500 603 
CFU, SH), S. aureus SH1000 purA, purB or pabA (1500 CFU). c-e, Growth of S. aureus mutants 604 
within embryos after injection with 1500 CFU of purA (c), purB (d) or pabA (e). Open circles, 605 
live and filled circles, dead embryos. f, Survival curves of pu.1 knockdown fish injected with S. 606 
aureus SH1000 (1500 CFU, SH), S. aureus SH1000 purA, purB or pabA (1500 CFU). 607 
 608 
Figure 2 The purA and purB S. aureus mutants require exogenous purines for growth 609 
a-c, Strains were grown in BHI (a), bovine serum (b) or human serum (c). Data are from three 610 
independent repeats, error bars represent standard errors. = JE2, = JE2-purB and = JE2-611 
purA. d, Growth of strains on CDM agar plates with or without adenine (20 μg ml-1)/guanine (20 612 
μg ml-1) after 24 h incubation aerobically at 37C. 613 
 614 
Figure 3 The pabABC operon is required for pathogenesis  615 
a,b, Female BALB/c mice (n = 10) were injected i.v. with 2x10
7
 CFU S. aureus SH1000 or 616 
4x10
7
 CFU S. aureus SH1000 pabA. Weight loss (a) and kidney (b) CFU were measured after 3 617 
days. c, Survival curves of fish injected with S. aureus SH1000 (1500 CFU, SH) or S. aureus 618 
SH1000 pabB. d, Survival curves of fish injected with S. aureus SH1000 (1500 CFU, SH) or S. 619 
aureus SH1000 pabC. e, Growth of parent (JE2), pabA, genetically complemented pabA 620 
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(integration of pJC002, JC006) or control integrated strain (pKASBAR empty plasmid in pabA 621 
mutant, JC007) on unsupplemented human blood agar (30% v/v). Plates were incubated 622 
aerobically at 37C for 48 h. f, Survival curves of fish injected with S. aureus SH1000 (1500 623 
CFU, SH), S. aureus SH1000 pabA (1500 CFU), S. aureus SH1000 pabA + pabABC operon 624 
(pJC002, 1500 CFU, JC010) or S. aureus SH1000 pabA with empty plasmid only (pKASBAR, 625 
1500 CFU, JC011). g, Survival curves of fish injected with S. aureus SH1000 (1500 CFU, SH) 626 
or S. aureus SH1000 pabA (1500 CFU, SH-pabA) followed by immediate immersion in either 627 
unsupplemented E3 medium (red) or supplemented with 7 μg ml-1 PABA (black). Uninjected 628 
fish were included as controls under each condition.  629 
 630 
Figure 4 Folate biosynthesis pathway and effect of lysed RBCs on S. aureus pabA growth 631 
a, The folate biosynthesis pathway and pyrimidine nucleotide salvage pathway (20, 21). Possible 632 
hypotheses for poor pabA growth on human blood are shown as (1) S. aureus Tdk is the target of 633 
competitive inhibition by human blood or (2) increased dTMP demand necessitates supplemental 634 
thymidine in S. aureus. b, Growth of S. aureus JE2 or JE2-pabA on non-vortexed human PPP or 635 
a decreasing ratio of vortexed:non-vortexed agar. Plates were incubated aerobically at 37C for 636 
48 h.  637 
 638 
Figure 5 An increased demand for thymidine is required for S. aureus growth on human 639 
blood  640 
a, Growth of S. aureus SH-thyA on MH agar. Media was either unsupplemented (top right box 641 
only) or contained a permissive amount of thymidine (500 ng ml
-1
). Increasing concentrations of 642 
human blood was added ranging from 1-50% (v/v) with MH agar base, containing thymidine 643 
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(500 ng ml
-1
). Plates were incubated aerobically at 37C for 24 h. b, At concentrations of human 644 
blood causing reduced thyA growth, biochemical complementation was achieved by addition of 645 
400 μg ml-1 thymidine. Plates were incubated aerobically at 37C for 24 h. 646 
 647 
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